Individuals with diabetes have an increased risk for hip and nonvertebral fractures.
Xeris Pharmaceuticals announced the launch of Gvoke HypoPen™ (glucagon) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 2 years and older.
A clinical perspective article details the recommended approach to manage diabetic ketoacidosis in patients with diabetes during the COVID-19 pandemic.
Continuous glucose monitoring is a safe and useful method to measure blood glucose levels in the hospital, especially during the COVID-19 pandemic.
The association of pemphigus with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) is assessed.
Presentation patterns are similar in patients with type 1 diabetes admitted with confirmed or suspected COVID-19.
Acute hyperglycemia affects brain metabolite concentration and performance on spatial working memory tasks in adolescents with type 1 diabetes.
The FDA has approved Lyumjev™ (insulin lispro-aabc injection; Lilly) to improve glycemic control in adults with type 1 and type 2 diabetes.
The FDA has approved Semglee™ (insulin glargine injection; Mylan and Biocon) to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
Researchers implemented an electronic medical record-based depressive symptom screen in type 1 diabetes mellitus adolescents seen in an outpatient clinic.
There is a high false-negative rate for lipohypertrophy diagnosis on physical examination in patients with type 1 or type 2 diabetes.
Golimumab was found to preserve β-cell function and reduce the need for exogenous insulin in young patients with type 1 diabetes.
Use of continuous glucose monitoring significantly decreases rates of hypoglycemia among children and adolescents who attend diabetes camps.
Body mass index (BMI) is associated with tracheal intubation and/or death within seven days among individuals with diabetes hospitalized for COVID-19.
The management of cardiovascular risk in patients with diabetes admitted with COVID-19 should be adapted to this population.
Researchers analyzed diabetes mobile applications to evaluate patient self-management capabilities and the compliance of these apps with diabetes care guidelines.
Hyperglycemic patients treated with insulin infusion to maintain tight glucose control were at lower risk for severe disease in COVID-19.
The FDA has accepted for review the New Drug Application for dasiglucagon HypoPal® Rescue Pen (Zealand Pharma) for the treatment of severe hypoglycemia.
Reacting to skyrocketing prices for insulin, the Trump Administration announced on Tuesday a new benefit that would limit Medicare recipients’ copays for insulin to a maximum of $35 a month and save them about $446 a year if they have prescription plans that offer the benefit.
Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.